Kitade Hiroaki, Yanagida Hidesuke, Yokoigawa Norio, Yamada Masanori, Hijikawa Takeshi, Kaibori Masaki, Matsui Kosuke, Ishizaki Morihiko, Yoshioka Kazuhiko, Kon Masanori
Dept. of Surgery, Kansai Medical University.
Gan To Kagaku Ryoho. 2015 Jul;42(7):863-5.
Case 1: A6 4-year-old man with hepatocellular carcinoma (HCC) had received local therapy repeatedly for 20 years. In 2012, he underwent hepatic right lobectomy for recurrence of HCC. Multiple recurrences were found in the hepatic remnant, and transcatheter arterial chemoembolization (TACE) was performed. Considering his condition, a small dose of sorafenib (200 mg per day) was administered. He complained of general fatigue, so we prolonged the administration interval (200 mg every other day). Thereafter, compliance improved and long-term stable disease (long SD), for more than 6 months, long SD was achieved. Case 2: A7 5-year-old man with HCC was treated by TACE repeatedly for multiple recurrences after liver resection (segment 6). In 2008, metastases to the thoracic vertebra and left rib were treated by radiation therapy and radiofrequency ablation, respectively. Subsequently, sorafenib (400 mg per day) was administered. We reduced the dose of sorafenib to less than 400 mg per day because of diarrhea, hypertension, and general fatigue. Thereafter, long SD was achieved despite the small dose of sorafenib. We report here 2 cases of HCC where we achieved long SD in spite of treating with a small dose of sorafenib.
病例1：一名64岁的肝细胞癌（HCC）男性患者接受了20年的局部治疗。2012年，他因HCC复发接受了肝右叶切除术。在肝残余组织中发现多处复发，遂进行了经动脉化疗栓塞术（TACE）。考虑到他的病情，给予小剂量索拉非尼（每天200毫克）。他主诉全身乏力，因此我们延长了给药间隔（每隔一天200毫克）。此后，依从性改善，实现了超过6个月的长期疾病稳定（长期SD）。病例2：一名75岁的HCC男性患者在肝切除术后（第6段）多次复发，接受了TACE治疗。2008年，分别对胸椎和左肋骨转移灶进行了放射治疗和射频消融。随后，给予索拉非尼（每天400毫克）。由于腹泻、高血压和全身乏力，我们将索拉非尼剂量减至每天小于400毫克。此后，尽管索拉非尼剂量较小，但仍实现了长期SD。我们在此报告2例HCC患者，尽管使用小剂量索拉非尼治疗，但仍实现了长期SD。
